AstraZeneca has committed to extending its Young Health Programme for a further five years (until 2025), spending $35 million to help educate young people on how to reduce the risks of non-communicable diseases.
AstraZeneca has committed to extending its Young Health Programme for a further five years (until 2025), spending $35 million to help educate young people on how to reduce the risks of non-communicable diseases.
The program was launched in 2010 as a focus of the company’s philanthropic role globally. Designed to reach young people in under-resourced communities, the disease prevention program has worked to reduce risk behaviors, such as smoking, alcohol abuse, poor diet, and lack of exercise.
“Non-communicable diseases continue to be the number one cause of death worldwide, and around 70% of those deaths can be linked to behavior that begins in adolescence,” said Marc Dunoyer, chief financial officer, in an Oct. 22, 2019 press release. “The Young Health Programme is AstraZeneca’s key philanthropic initiative that has already reached more than three million young people across the world. I’m proud to say that this extra funding will see the program expand into Thailand, Egypt, Colombia and beyond, and reach a further five million young people by 2025.”
Rose Caldwell, chief executive, Plan International UK, added, “Ten years ago we co-founded the Young Health Programme with AstraZeneca, and at the time, we were entering a space where we knew there was a lot that needed to be done. The health of young people was not high on the global agenda and their rights were not being recognized. What we have accomplished together is a true reflection of the trust and collaboration of our partnership and learnings shared across the globe from Brazil to Indonesia. We are moving in the right direction with a marked increase in global health discussions addressing the health rights of young people and the threat of non-communicable diseases. Together over the next five years we will continue to champion the rights of young people.”
Source: AstraZeneca
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.